Osmol Therapeutics
New Haven, US · Founded 2016 · Delaware corporation · 6 employees on LinkedIn
Osmol Therapeutics is a preclinical-stage biotech developing OSM-0205, an intravenous drug intended to prevent chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI) in cancer patients receiving taxane-based therapy. The drug targets the interaction that triggers a calcium surge leading to neuronal damage, aiming to allow optimal chemotherapy dosing.
Founders & leadership
BD
Brian DixonExecutive
BL
Bob LinkePresident & CEO
RW
Ron WeitzmanChief Medical Officer
Board
BE
Barbara EhrlichChief Scientific Advisor
Reported raises · per SEC filings
Form D private placements$2.9M disclosed across 2 rounds · 2016–2022
▶$2.3MraisedFeb 2022 · 4 investors · BiotechnologyRule 506(c)
▶$2.3MraisedFeb 2022 · 4 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Michael EhrlichDirector
- Robert BermanDirector
- Robert LinkeExecutive Officer, Director
- Vlad CoricDirector
- Offering amount
- $7.5M
- Amount sold
- $2.3M
- First sale
- Feb 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$550KraisedJan 2017 · 4 investors · BiotechnologyRule 506(b)
▶$550KraisedJan 2017 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Brian DixonExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $550K
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapOS Therapies5 shared keywords
Applied Therapeutics5 shared keywordsApplied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need. Its Aldose Reductase Inhibitor franchise is in development across disease areas including Galactosemia and SORD Deficiency.
Companies competing with Osmol Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Osmol Therapeutics do?
- Osmol Therapeutics is a preclinical-stage biotech developing OSM-0205, an intravenous drug intended to prevent chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI) in cancer patients receiving taxane-based therapy. The drug targets the interaction that triggers a calcium surge leading to neuronal damage, aiming to allow optimal chemotherapy dosing.
- How much funding has Osmol Therapeutics raised?
- Osmol Therapeutics has disclosed $2.9M raised across 2 rounds.
- Where is Osmol Therapeutics headquartered?
- Osmol Therapeutics is headquartered in New Haven, US.